The University of Chicago Header Logo

Connection

Stephen Hanauer to Immunologic Factors

Back to Details
This is a "connection" page, showing publications Stephen Hanauer has written about Immunologic Factors.
Stephen Hanauer
Connection Strength
2.894
Immunologic Factors
  1. Reply: To PMID 25311382. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2384-5.
    View in: PubMed
    Score: 0.456
  2. Heading back to the trough (levels of biologics in IBD). Clin Gastroenterol Hepatol. 2015 Mar; 13(3):548-51.
    View in: PubMed
    Score: 0.432
  3. Disease modification in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012 Sep; 10(9):954-5.
    View in: PubMed
    Score: 0.368
  4. Update on the management of ulcerative colitis. Curr Gastroenterol Rep. 2011 Oct; 13(5):475-85.
    View in: PubMed
    Score: 0.350
  5. Inflammatory bowel disease. Expert Rev Clin Immunol. 2010 Jul; 6(4):499-500.
    View in: PubMed
    Score: 0.321
  6. Optimizing conventional therapies for inflammatory bowel disease. Curr Gastroenterol Rep. 2009 Dec; 11(6):496-503.
    View in: PubMed
    Score: 0.308
  7. Biologics in peri-operative management of Crohn's disease. Acta Gastroenterol Belg. 2001 Apr-Jun; 64(2):191-2.
    View in: PubMed
    Score: 0.169
  8. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1042-50.e2.
    View in: PubMed
    Score: 0.100
  9. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):696-702.e1.
    View in: PubMed
    Score: 0.079
  10. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010 Jul; 8(7):600-9.
    View in: PubMed
    Score: 0.078
  11. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol. 2008 Jan 21; 14(3):354-77.
    View in: PubMed
    Score: 0.068
  12. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut. 2007 Sep; 56(9):1181-3.
    View in: PubMed
    Score: 0.066
  13. Review article: the long-term management of ulcerative colitis. Aliment Pharmacol Ther. 2004 Oct; 20 Suppl 4:97-101.
    View in: PubMed
    Score: 0.054
  14. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate). Curr Gastroenterol Rep. 2021 Dec 16; 23(12):30.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.